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Summary 
Background: Acute lymphoblastic leukemia (ALL) is known
as the most prevalent pediatric malignancy all around the
world. Identification of specific biomarker is necessary for
early diagnosis and effective therapy. It is believed that
Adenosine deaminase (ADA) as an enzyme involved in the
purine salvage pathway increases in ALL patients. Herein,
the quantity and pattern of ADA isoenzymes were surveyed
among ALL patients in comparison to healthy subjects. 
Methods: Serum and RBC samples of three different groups
of ALL patients, including newly diagnosed cases without any
drugs administration, subjects with the relapsed disease,
patients in the remission stage after therapy, and the healthy
subjects were enrolled in the study. Then, the activity and
pattern of ADA1, ADA2 and ADA1+cp were determined
using ADA kit and electrophoresis on SDS-PAGE, respective-
ly. To confirm the presence of ADA enzyme, the fresh
serums, extractions from erythrocytes, JM cell line as a
human T lymphocyte line and J774 A.1 as mouse monocyte
line were electrophoresed on 1.2% agarose gel and stained
with the specific dye.
Results: The activities of ADA1 isoenzyme and total ADA in
new cases and subjects with the relapsed disease were sig-
nificantly higher than their activities in the patients in the
remission stage and healthy controls (p<0.001). The
unbounded ADA1 isoenzyme was found to exist in the ery-
throcyte, lymphocyte and monocyte. But in serum, all the
ADA1 was bounded to the cp protein. 
Kratak sadr`aj
Uvod: Akutna limfnoblastna leukemija (ALL) je poznata
kako naju~estalija pedijatrijska maligna bolest {irom sveta.
Identifikacija specifi~nih biomarkera je potrebna za ranu
dijagnozu i efikasnu terapiju. Smatra se da je adenozin dea -
minaza (ADA) enzim koji je uklju~en u metabolizam purina
pove}ana kod ALL pacijenata. U ovom radu izu~avan je
kvantitativni profil ADA izoenzima kod ALL pacijenata u
odnosu na zdrave ispitanike.
Metode: Uzorci seruma i eritrocita kod tri razli~ite grupe
ALL pacijenata, uklju~uju}i novo dijagnostikovane slu~a -
jeva koji nisu primali lekove, pacijente sa povratkom bolesti
i pacijente u remisiji posle terapije, kao i grupa zdravih
ispitanika, su sakupljani i ispitivani na aktivnost i profil
ADA1, ADA2 i ADA1+cp primenom ADA kita odnosno
SDS-PAGE elektroforezom. Da bi se potrvrdilo prisustvo
ADA enzima, sve`i serumi, hemolizati eritrocita, JM linija
}elija kao humana T limfocitna linija I J774 A.1 i mi{ija
mono citna linija analizirana je elektroforetski na 1.2%
agaroza gelu i bojena specifi~nim bojama.
Rezultati: Aktivnost ADA1 izoenzima i ukupne ADA u
novim slu~ajevima i kod pacijenata sa povratkom bolesti je
bila zna~ajno vi{a nego kod pacijenata u stanju remisije
bolesti odnosno kod zdravih ispitanika (p < 0.001). Ne -
sum njivo da ADA1 enzim postoji u eritrocitima, limfocitima
i monocitima. Me|utim u serumu ADA1 je vezana za cp
protein.
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Introduction
Acute lymphoblastic leukemia (ALL), the most
prevalent malignancy among children includes
approximately 25% of pediatric cancers in developed
countries (1). Abnormal transformation, epigenetic
and genetic aberrations in the progenitor cells of T
and B cell lineages results in ALL. Additionally, in
young cases, recurred ALL originated from B cell lin-
eage causes a high rate of cancer death (2–4).
Despite the aggressive nature of ALL, it has
been shown that individual therapy in developed
health centers, nowadays, leads to high rate remis-
sion and the long–lasting survival time in patients.
Therefore, rapid and facile detection of ALL is neces-
sary to save the lives in all countries (5, 6).
Adenosine deaminase (ADA) (adenosine amino -
hydrolase, EC 3.5.4.4) is a polymorphic enzyme
involved in the purine salvage pathway. It converts
adenosine and deoxyadenosine to inosine and deoxyi-
nosine, respectively. The ADA activity in lymphocytes,
especially, T cells, is higher than erythrocytes. More -
over, the activity of this enzyme has some variations
during differentiation phases of T-cells and is greater
among immature T-cells (7).
In physiological conditions, there are three dis-
crepant isoenzymes in the human tissues, including
ADA1, ADA1+cp and ADA2 (8). ADA1 is the mono -
meric protein that is distributed in all tissues through-
out the human body such as lymphocytes and mono-
cytes. ADA2 is another isoenzyme expressed in the
monocytes and macrophages and secreted to the
serum by both of the cells (9). ADA1+cp consists of
two ADA1 molecules linked through 280 kDa binding
protein (6). 
In addition to developing the immune system,
ADA plays a momentous role in proliferation, differen-
tiation, and maturation of lymphocytes (10). Since the
quantity of adenosine in inflammatory responses is
controlled via ADA activity, alteration of ADA level in
plasma is seen in a wide variety of diseases especially
those related to the immune system and hematologic
malignancies. The previous findings reported that the
ADA quantity and activity increase in serum of chil-
dren and young patients with ALL. Therefore, this
enzyme could be a suitable marker to detect and mon-
itor ALL, together with other alternatives (11, 12).
In this study, we analyzed the activity and isoen-
zyme patterns of ADA among four different groups of
ALL patients including newly diagnosed cases without
any drugs administrations, subjects with the relapsed
disease, and patients in the remission stage after ther-
apy and compared their outcomes with those of the
healthy control subjects.
Materials and Methods
Patients and serum samples
This study was a cross-sectional research, been
performed in Tehran, Iran. Fifty-four patients suffered
from ALL who referred to Ali Asghar children’s hospi-
tal from April 2014 to March 2015 were included in
the study. All the patients were 6–12 year old children
without the other hematological disease. Twenty-two,
18 and 14 out of 54 patients were newly diagnosed
cases without administration of any drugs (known as
new cases in this text), subjects with the relapsed dis-
ease, and patients in the remission stage after thera-
py, respectively. ALL patients were diagnosed based
on the bone marrow examination, lung radiography,
and complete blood cell analysis. Thirty healthy sub-
jects without leukocytosis and lymphocytosis were
tested as controls. The consent forms were complet-
ed and signed by the children's parents. This study
was designed and approved by the Ethics Committee
of Pasture Institute of Iran and performed in accor-
dance with its guideline's.
Samples collection
To provide the RBC and serum samples, the
blood specimen was collected from each patient and
centrifuged at 3000 rpm for 15 min. The RBC frac-
tion and plasma were separated and transferred to
fresh tubes and used for further investigations.
ADA enzyme assay
The ADA enzyme activity was determined by
ADA kit (DIAZYME Company) according to the man-
ufacturer's guideline. The kit contains glutamate dehy-
drogenase, which consumes the NH4+ produced by
ADA in step one along with NADPH, leading to the
release of  NADP+. Reduction of NADPH results in
decreased absorbance at 340 nm that was an indica-
tion of total ADA quantity in the serum sample.
To assess ADA2 activity, the erytro-9-(2-hydroxy-
3-nonyl) adenine (EHNA) (Sigma, Germany) was
Conclusions: ADA1 is the key isoenzyme elevating in ALL
patients, therefore this isoenzyme could be a useful bio-
marker to diagnose ALL patients and monitor their thera-
pies.
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used to inhibit ADA1 activity, specifically. The ADA2
isoenzyme activity was measured in the presence of
0.1 mmol/L EHNA after 20 min at 340 nm using
Automatic Analyzer (Technicon RA-1000). Finally, the
ADA1 isoenzyme activity was assayed by subtracting
the activity of ADA2 from that of the total ADA.
Furthermore, to identify the pattern of ADA1,
ADA2, and ADA1+cp isoenzymes, electrophoresis
on the SDS-PAGE (10, 8, and 6%) was done, respec-
tively. To visualize the protein bands, the SDS-PAGE
was stained with Coomassie blue.
Enzyme assay of ADA of RBCs
Because of the binding of ADA1 to cp protein
in the serums of ALL patients, RBC samples were
applied to assess the free ADA1 isoenzyme. To pro-
tect the enzyme activity, the RBCs were washed 3
times with normal saline. An aliquot of washed ery-
throcytes was lysed with toluene and cold water (1
mL RBC + 0.5 mL toluene + 1 mL cold water) and
centrifuged at 15000 × g for 40 minutes. After then,
the lysed RBC samples were analyzed on 6–10%
SDS-PAGE to separate the ADA isoenzymes.
Specific ADA staining 
The presence of ADA enzyme was confirmed by
electrophoresis of the fresh serums collected from
patients and healthy subjects on 1.2% agarose gel at
4 °C for 3 h.Then stained with the specific dye con-
taining sodium phosphate (0.1 mol/L, pH=7),
adenosine, phenazinemetosulphate, di-methyl tiazolyl
tetrazolium bromide (MTT), nucleoside phosphory-
lase (1 mg/mL), gezantin oxidase (10 mg/mL) for 45
min at 37 °C. Standard ADA was examined along
with the samples as a control (13).
Furthermore, to determine the pattern of ADA
isoenzymes in the lymphocytes and monocytes, the
cell extraction of JM cell line as a human T lympho-
cyte line, and J774 A.1, as a mouse monocyte line
were prepared using freezing-thawing method (12).
The cell extracts were applied to 1.2% agarose gel
and after electrophoresis, stained using the specific
dye as described above.
Statistical analysis
To compute the difference between the different
patient and control groups, the t-test and ANOVA
were done by using SPSS 17 software (Chicago,
USA). The p-value less than 0.05 (p<0.05) was con-
sidered as a significant difference.
Results 
In the current study, the enzymatic activity of
ADA and its isoenzymes was analyzed among patients
with ALL and healthy subjects. The mean value of
ADA1 activity was found to be 22, 23.2, 5.07 and
5.83 IU/L in the new cases, subjects with the
relapsed disease, those in the remission stage and
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Figure 1 Enzymatic activity of adenosine deaminase isoenzymes in serums of ALL patients and control groups. 
“***” indicates p<0.001. 
The activity of ADA1 isoenzyme and total ADA in the new cases and subjects with relapsed disease were found to be significantly
higher than those of the patients at remission stage and the healthy controls.
healthy controls, respectively. However, the activity of
ADA2 was 11.5, 11.3, 9.7 and 4.57 IU/L in new
cases, subjects with the relapsed disease, and
patients in the remission stage, and healthy controls,
respectively. No significant difference was seen in the
ADA2 activity between the tested groups. The activity
of total ADA was 32.7, 34.5, 14.5 and 15.4 IU/L in
the new cases, subjects with the relapsed disease,
and patients in the remission stage, and healthy con-
trols, respectively. As illustrated in Figure 1, the activ-
ity of ADA1 isoenzyme and total ADA in the new
cases and subjects with the relapsed disease were sig-
nificantly higher than those of patients in the remis-
sion stage and the healthy controls (p<0.001).
Nevertheless, there was not a significant difference,
either between new cases and those at relapsed step
or patients in the remission stage and healthy con-
trols.
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Figure 2 Illustration of ADA1 isoenzyme within RBC on 10%
SDS-PAGE. The molecular weight of ADA1 isoenzyme is
approximately 35 KDa. Lanes 1 and 2 is related to the healthy
subjects; lanes 3, 4, 5 and 6 are the samples of the ALL
patients; M indicates the low molecular weight protein marker.
Figure 4 Determination of molecular weight of serum
ADA1+cp complex on 6% SDS-PAGE. Lanes 1 to 6 show
serum of ALL patients; Lanes 7 and 8 are related to serum of
healthy subjects; M indicates the high molecular weight pro-
tein marker.
Figure 5 Illustration of ADA isoenzymes on 1.2% agarose
gel stained using the specific dye. Lane 1, 2, 3 and 4 are
related to the serum of healthy subject, patient serum con-
taining the erytro-9-(2-hydroxy-3-nonyl) adenine, serum of
ALL and ALL patient serum, respectively.
Figure 3 Comparison of the status of ADA1 isoenzyme of
intact serum, heated serum, serum without SDS or 2-ME,
and RBC. Lane1 is heated serum of a healthy case; lane 2 is
related to the heated serum of ALL patient; lanes 3, and 4
show erythrocyte ADA1 isoenzyme; lanes 5 and 6 show the
serum of ALL patients without SDS and 2-ME; M indicates
the low molecular weight protein marker.
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Regarding binding of ADA1 to cp protein in
serum, the patterns of ADA1 isoenzyme in RBC and
serum samples were assessed by the electrophoresis
on 10% SDS-PAGE (Figures 2 and 3, respectively). The
molecular weight of the unbounded ADA1 isoenzyme
was estimated to be approximately 35 KDa. According
to the Figures 2 and 3, RBC has a free ADA1 isoen-
zyme while, intact serums, heated, and SDS or 2-mer-
captoethanol treated serum samples were lack of free
ADA1 in both, ALL patients and healthy controls. 
Figure 4, depicts the pattern of the ADA1+cp
protein in serum samples of ALL patients and healthy
controls. The band with a molecular weight of 280
KDa is a representative of the ADA1+cp protein. This
data showed that only bounded ADA, as ADA1+cp
form; exists in the serums of both, ALL patients and
the healthy controls.
Figures 5 and 6 show that unbounded ADA1
isoenzyme exists in the erythrocytes, lymphocytes, and
monocytes. However, in serum, ADA1 isoenzyme is
fully bounded to the cp protein. Furthermore, unlike
monocytes, lymphocytes and erythrocytes lack ADA2.
Discussion
It is believed that ADA has a momentous role in
the developing of the immune system and different
growth stages of T cell and B cell lymphocytes. The
increased quantity and activity of ADA is an accepted
indicator for lymphocytes immaturity (10). Similar to
the abnormalities in the immune system, several
malignancies such as breast, colorectal, lung, and
ovarian cancer and etc. are accompanied with aug-
mentation of ADA activity.
In ALL patients, the presence of genetic and epi-
genetic abnormality in the stem cells of T and B cell lin-
eages located in bone marrow results in over-prolifera-
tion of progenitors with high speed and release of
numerous immature and undifferentiated lymphocytes
in the peripheral blood (8, 14). Increased proliferation
leads to salvage of nucleoside, therefore, ADA quantity
and activity enhance to rectify the purine limitation. 
To our knowledge, there are few studies working
out on the ADA status in ALL patients. In the research
performed by Mishra et al. (8), the significant higher
ADA activity was reported among ALL patients com-
pared to that of the control group. However, they found
no different ADA activities between ALL patients and
those with either leukocytosis and lymphocytosis (8). In
addition, in another study (9) it is observed the higher
level of serum ADA but reduced lymphocytes count
among patients suffered from ALL comparing with the
normal individuals. Our findings viewed the significant-
ly higher activity of ADA in ALL patients in comparison
to the healthy subjects. In this study, data revealed that
active ALL groups, new cases, subjects with the
relapsed disease have a higher ADA1 activity while
there was no increased ADA activity among patients in
the remission stage and those in the healthy control
group. The previous researchers have assessed the
activity of the total ADA. In the present study, we have
analyzed the activity of both ADA1 and ADA2 isoen-
zymes in the patients with ALL and the healthy control
group. Our results revealed that ADA1 is a key isoen-
zyme, considerably over-expressed in ALL malignancy.
However, we identified no significant alterations in the
activity and quantity of ADA2 in the patients studied.
Although the present study was done on three
different groups of patients related to ALL, two ADA
isoenzymes, and total ADA, there are few limitations
in it. The number of patients in the current study is
few and to confirm the findings, it is necessary to per-
form the study in the larger sample sizes. In addition,
the genetic and epigenetic profiles of the patients in
each tested groups could be supporting to decide if
the application of ADA assay might be considered for
ALL monitoring and detection.
Conclusion 
Overall, ADA activity and quantity increase in
ALL patients and relapsed stage of the disease. In
addition, ADA1 is the key isoenzyme elevating in ALL
patients, therefore, it might be a useful biomarker
together with other approaches to diagnose ALL
patients and monitor their therapies.
Acknowledgments. This study has been granted
by Pasteur Institute of Iran. We would like to thank the
staff of Biochemistry Department, Pasteur Institute of
Iran, for their helpful assistance.
Conflict of interest statement
The authors stated that they have no conflicts of inter-
est regarding the publication of this article.
Figure 6 The pattern of ADA isoenzymes in blood cells and
serum on 1.2% agarose gel. Lane 1, 2, 3, and 4 are related
to erythrocyte extract, JM cell line extract (as T cell lympho-
cytes), J774 A.1 cell line extract (as a monocyte) and serum,
respectively. 
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